Cardiff Oncology, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports the results of the Annual Meeting of Stockholders held by Cardiff Oncology, Inc. on June 11, 2026. The company is incorporated in Delaware and trades on The Nasdaq Stock Market LLC under the symbol CRDF.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting outcomes.
Material Changes and Voting Results
A total of 41,614,848 shares were represented at the meeting, constituting a quorum. The following matters were submitted to a vote:
- Proposal 1 (Director Elections): All six nominees were elected. Votes were overwhelmingly in favor with zero "Against" votes for any nominee. Significant broker non-votes were recorded for each director.
- Proposal 2 (Auditor Ratification): Stockholders ratified the appointment of BDO USA, P.C. as the independent registered public accounting firm for the fiscal year ended December 31, 2026.
- Proposal 3 (Equity Plan Amendment): Stockholders approved an amendment to the 2021 Equity Incentive Plan to increase the number of issuable shares to 15,150,000. This proposal received significant opposition, with 8,063,520 votes cast against it.
- Proposal 4 (Say-on-Pay): The advisory vote on executive compensation was approved.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management commentary on financial outlook, specific risks, contingencies, or unusual items beyond the voting results.
Investor Verification Checklist
- Verify the implications of the significant "Against" votes (approx. 8 million shares) on the Equity Incentive Plan amendment.
- Confirm the total number of shares outstanding to contextualize the 41.6 million shares represented at the meeting.
- Review the Definitive Proxy Statement filed on April 23, 2026, for detailed rationale behind the equity plan increase and executive compensation.
- Monitor the company's financial status in upcoming 10-Q or 10-K filings, as this 8-K contains no financial data.